Related Experiment Video
Updated: Aug 13, 2026

03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
490
Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports
Nai-Si Huang1, Jia-Ying Chen1, Yan Meng2
1Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Oral Oncology
|September 22, 2024
Summary
Pralsetinib shows promise as a neoadjuvant treatment for locally advanced RET-fusion positive papillary thyroid cancer (PTC). This targeted therapy may improve surgical outcomes for patients with unresectable tumors.
Area of Science:
- Oncology
- Molecular Targeted Therapy
- Surgical Oncology
Background:
- Locally advanced thyroid cancer (5-10% of cases) presents challenges for surgical resection.
- Neoadjuvant targeted therapy offers potential to downstage tumors, enabling surgery.
- Pralsetinib, a RET inhibitor, is approved for advanced RET-altered thyroid cancer, but its neoadjuvant role is unproven.

